Figure 1.
Figure 1. Incidence of invasive adenovirus infection, disseminated disease and overall survival. (A) Probability of invasive AdV infection and disease. In the cohort of patients investigated, the 1-year cumulative incidence of invasive AdV infection after SCT (dashed curve), documented by virus detection in peripheral blood, was 8% (± 8%), that of AdV-associated disease (solid curve) 6% (± 6%). (B) Probability of disease after AdV detection in PB. The cumulative incidence of disease was 73% (± 10%) within 60 days after the first AdV-positive PCR test in PB. (C) Probability of survival in patients with AdV-positive or -negative PCR tests. The black (bottom) curve indicates the overall survival in patients with AdV positivity in PB. The 1-year probability of survival (pSU) in this cohort was 18% (± 9%). The 2 upper, nearly identical curves illustrate the overall survival in patients who tested AdV negative in PB, but positive at 1 or 2 other sites (dashed gray curve; 1-year pSU of 64% [± 10%]), and in AdV-negative patients (solid gray curve; 1-year pSU of 67% [± 5%]). The difference between patients positive for AdV in PB and the other 2 cohorts illustrated is highly significant (P < .001). By contrast, there was no statistically significant difference in pSU between AdV-negative patients and patients who tested AdV positive at sites other than PB (P = .706).

Incidence of invasive adenovirus infection, disseminated disease and overall survival. (A) Probability of invasive AdV infection and disease. In the cohort of patients investigated, the 1-year cumulative incidence of invasive AdV infection after SCT (dashed curve), documented by virus detection in peripheral blood, was 8% (± 8%), that of AdV-associated disease (solid curve) 6% (± 6%). (B) Probability of disease after AdV detection in PB. The cumulative incidence of disease was 73% (± 10%) within 60 days after the first AdV-positive PCR test in PB. (C) Probability of survival in patients with AdV-positive or -negative PCR tests. The black (bottom) curve indicates the overall survival in patients with AdV positivity in PB. The 1-year probability of survival (pSU) in this cohort was 18% (± 9%). The 2 upper, nearly identical curves illustrate the overall survival in patients who tested AdV negative in PB, but positive at 1 or 2 other sites (dashed gray curve; 1-year pSU of 64% [± 10%]), and in AdV-negative patients (solid gray curve; 1-year pSU of 67% [± 5%]). The difference between patients positive for AdV in PB and the other 2 cohorts illustrated is highly significant (P < .001). By contrast, there was no statistically significant difference in pSU between AdV-negative patients and patients who tested AdV positive at sites other than PB (P = .706).

Close Modal

or Create an Account

Close Modal
Close Modal